Zatolmilast is a phosphodiesterase IV inhibitor.
For research use only. We do not sell to patients.
| Name | Zatolmilast |
|---|---|
| Iupac Chemical Name | (4-{[2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl]methyl}phenyl)acetic acid |
| Synonyms | Zatolmilast; BPN14770; BPN-14770; BPN 14770 |
| Molecular Formula | C21H15ClF3NO2 |
| Molecular Weight | 405.80 |
| Smile | O=C(O)CC1=CC=C(CC2=CC(C3=CC=CC(Cl)=C3)=NC(C(F)(F)F)=C2)C=C1 |
| InChiKey | LTSUMTMGJHPGFX-UHFFFAOYSA-N |
| InChi | InChI=1S/C21H15ClF3NO2/c22-17-3-1-2-16(12-17)18-9-15(10-19(26-18)21(23,24)25)8-13-4-6-14(7-5-13)11-20(27)28/h1-7,9-10,12H,8,11H2,(H,27,28) |
| CAS Number | 1606974-33-7 |
| Related CAS |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: WHO Drug Information, Vol. 34, No. 2, 2020
2: Ricciarelli R, Brullo C, Prickaerts J, et al. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. Sci Rep. 2017;7:46320. Published 2017 Apr 12. doi:10.1038/srep46320
3: Gurney ME, Nugent RA, Mo X, et al. Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders. J Med Chem. 2019;62(10):4884-4901. doi:10.1021/acs.jmedchem.9b00193